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Computer-assisted morphometry can provide precise measurement of hepatic fibrosis on a con-
tinuous scale. Previous morphometric studies of large cohorts of patients with treatment refrac-
tory chronic hepatitis C have shown a mean increase in fibrosis of 30% to 58% in 1 year. The aim
of the present study was to quantify fibrosis progression in biopsy specimens obtained over 1.5 to
5 years from three groups of patients with baseline bridging fibrosis or cirrhosis (Ishak stages 3-6)
enrolled in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. The main
group of 346 lead-in nonresponders (viremic after 24 weeks of peginterferon-ribavirin therapy)
had a mean fibrosis increase of 61% over pretreatment baseline after 2 years and 80% after 4
years. In contrast, the 78 breakthrough/relapse patients (undetectable serum hepatitis C virus
RNA after 24 weeks of peginterferon-ribavirin and receiving antiviral therapy for 48 weeks)
showed a mean increase in fibrosis of 48% when biopsied 36 months from pretreatment baseline
but no further increase at 60 months. Finally, the 111 express patients with baseline biopsies
following unsuccessful peginterferon-ribavirin outside the trial had significantly more baseline
fibrosis than the others but an increase of only 21% after 21 months and a slight decrease at 45
months. Maintenance therapy with low-dose peginterferon had no effect on fibrosis changes in
any of the groups. Conclusion: Morphometry demonstrated complex, nonlinear changes in
fibrosis over time in this heterogeneous cohort of patients with interferon-refractory chronic
hepatitis C. (HEPATOLOGY 2009;50:1738-1749.)
Progression of hepatic fibrosis is the mechanism bywhich chronic hepatitis C leads to cirrhosis anddecompensated liver disease. Consequently, inter-
est is high in developing therapeutic options for patients
who are not candidates for antiviral treatment as well as
those who do not achieve a sustained virological response
to antiviral therapy; these patients remain at risk for con-
tinuing fibrosis progression and the clinical consequences
of hepatic decompensation and hepatocellular carcino-
ma.1-3 Because chronic hepatitis C takes decades to evolve
into cirrhosis, and even longer to progress toward decom-
pensation, demonstration of survival benefit resulting
from antiviral therapy would require large treatment trials
of very long duration; therefore, treatment benefit in
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many clinical trials has been demonstrated reliably by
assessing fibrosis stage in paired liver biopsies obtained
before and after a course of therapy.
In most studies that have relied upon liver biopsy to
evaluate changes in fibrosis, semiquantitative scoring sys-
tems have been used that have a limited range of catego-
ries of severity, such as the Metavir score4 (five stages) or
the Ishak score5 (seven stages). An alternative to semi-
quantitative fibrosis scores is direct measurement of the
amount of fibrosis in the biopsy specimen by computer-
assisted morphometric image analysis. In contrast to
semiquantitative fibrosis scores that rely on quantity and
location of, and architectural distortion caused by fibrosis,
morphometry determines the proportion of collagenous
tissue in a specimen, regardless of location, and provides
precise measurements on a continuous scale. Within any
given semiquantitative stage, a wide range of collagen may
be present, and considerable overlap exists within Metavir
and Ishak stages.6,7 Accurate morphometric studies, how-
ever, require high-quality, unfragmented liver biopsy
specimens of sufficient size, because fibrous tissue is un-
derrepresented in small, fragmented specimens of fibrotic
livers. Morphometry is also subject to sampling variabili-
ty,8 but when used to show differences between treatment
groups in an adequately powered study, morphometry has
the potential to be the most sensitive means of showing
changes in the quantity of fibrosis.7
Even though clinical and histologic progression is usu-
ally very slow, in two previous morphometric analyses of
antifibrotic agents tested in randomized controlled trials,
investigators found that the actual quantity of fibrous tis-
sue increased at a rapid rate in patients with treatment-
resistant chronic hepatitis C. In one study of 245 patients
with advanced fibrosis and cirrhosis (Ishak stage 4-6)
treated with interferon (IFN)-1b or placebo, the mean
collagen content of the liver biopsies increased by 58% in
only 48 weeks.7 Similarly, in a trial of the peroxisome
proliferator-activated receptor agonist antifibrotic agent
farglitazar compared with placebo in patients with mod-
erate (Ishak stage 2-4) precirrhotic fibrosis, the mean he-
patic collagen content increased by 30% in 52 weeks.9
Such changes may not have direct clinical significance,
especially in patients with relatively little baseline fibrosis,
but the ability to detect the change suggests that mor-
phometry is a more useful tool than histologic staging for
clinical trials of antifibrotic agents.
The Hepatitis C Antiviral Long-term Treatment
Against Cirrhosis (HALT-C) Trial provided a unique op-
portunity to evaluate morphometry for assessing changes
in liver fibrosis over several years in patients with chronic
hepatitis C and moderate to advanced fibrosis. In the trial,
we enrolled 1,050 prior nonresponders to pegylated IFN
and ribavirin with compensated liver disease and bridging
fibrosis or cirrhosis. Subjects were randomized to receive
either weekly injections of 90 g peginterferon alfa-2a or
no therapy for 3.5 years. Over the course of the trial, we
found no difference between the peginterferon-treated
and nontreated groups in the development of clinical out-
comes or in progression from precirrhotic fibrosis to cir-
rhosis on liver biopsy.10 In this paper, we report results of
histologic and morphometric analyses of fibrosis in liver
biopsies obtained at baseline (up to 18 months before
randomization), at approximately 18 months after ran-
domization (study month 24), and at approximately 42
months after randomization (study month 48). We hy-
pothesized that morphometric image analysis would
demonstrate a linear increase in collagen content over
time and might show an effect of maintenance therapy on
fibrosis progression, even if standard histologic scoring
did not.
Patients and Methods
The design and results of the HALT-C Trial have been
reported.10,11 To be eligible for entry into the trial, pa-
tients at 10 United States Medical Centers had to be
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nonresponders to prior IFN therapy and had to have
bridging fibrosis or cirrhosis on liver biopsy. Potential
participants were excluded if they had another concurrent
liver disease, a history of hepatic decompensation or hep-
atocellular carcinoma, any contraindication to IFN ther-
apy, or any other medical or psychiatric condition that
could interfere with their completion of the trial.
Recruitment for the trial began in August 2000 and
ended in August 2004. Initially, all patients underwent a
24-week lead-in phase of treatment with combination,
full-dose peginterferon alfa-2a and ribavirin. Patients who
were still viremic after 20 weeks of treatment (lead-in
nonresponders) were randomized to receive no further
therapy (controls) or low-dose (90 g/week) peginter-
feron (maintenance) for the next 3.5 years (Fig. 1). Pa-
tients with undetectable serum hepatitis C virus (HCV)
RNA after 20 weeks of treatment were categorized as re-
sponders and continued to receive full-dose peginterferon
and ribavirin for a total of 48 weeks. Those who were
found thereafter to have detectable HCV RNA while re-
ceiving treatment (breakthrough patients) or after com-
pleting the 48 weeks of therapy (relapse patients) were
eligible for randomization for the following 3.5 years
(breakthrough/relapse patients). After combination
peginterferon and ribavirin was approved by the U.S.
Food and Drug Administration, patients who had re-
ceived the equivalent of lead-in treatment outside the trial
were also allowed to enter the randomized phase (express
patients). Of the 1,050 patients enrolled in the random-
ized phase of the study, 662 were lead-in nonresponders,
151 were breakthrough/relapsers, and 237 were express
patients.
Liver biopsies were evaluated for necroinflammatory
changes, fibrosis, steatosis, and other findings by consen-
sus of a committee of 12 pathologists, at least 8 of whom
were present at each scoring session. The Ishak fibrosis
score5 was used as a primary endpoint in the trial. All
patients were required to have a baseline liver biopsy
showing bridging fibrosis (Ishak stages 3-4) or cirrhosis
(Ishak stages 5-6) within 12 months of enrollment in the
trial. Exceptions were allowed for patients with stage 2
(portal fibrosis) if a previous biopsy had shown unequiv-
ocal bridging fibrosis. For express subjects, baseline biop-
sies were obtained following unsuccessful peginterferon-
ribavirin outside the trial. Repeat biopsies were performed
at 18 months after entering the randomized phase (biopsy
2) and after another 24 months (biopsy 3) unless the
patient refused, had a contraindication to biopsy, had a
study-terminating clinical outcome, or had withdrawn
from the trial.
Morphometric Image Analysis of Hepatic Fibrosis.
We used liver biopsy sections stained with Sirius red for
assessment of hepatic collagen content as described7 with
Image Pro Plus 6.0 imaging software (Media Cybernetics,
Silver Spring, MD) after editing of the digitized images to
remove technical artifacts and extraneous tissue, such as
Fig. 1. Design of the HALT-C Trial, showing the source of the three cohorts of patients used in morphometric analyses of fibrosis. Lead-in
nonresponder patients (blue lines) were those who remained viremic during the lead-in phase of peginterferon/ribavirin for 6 months and were then
randomized to maintenance peginterferon or the untreated control group. These patients underwent baseline liver biopsies before the lead-in phase
and approximately 24 and 48 months later. Breakthrough/relapse patients (green lines) developed undetectable HCV RNA during the lead-in phase
of peginterferon/ribavirin and completed 12 months of therapy and 6 months of follow-up. Those who became viremic while still receiving therapy
(breakthrough) or during follow-up (relapse) were randomized to maintenance or untreated control groups. These patients had baseline biopsies
before the lead-in phase and approximately 36 and 60 months later. Express patients (red lines) received the equivalent of the lead-in phase outside
the trial but remained viremic. Most of these patients had baseline biopsies immediately before randomization to maintenance peginterferon or the
control group. Subsequent biopsies were at 18 and 42 months after randomization. PegIFN, peginterferon.
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skin or muscle as well as Glisson’s capsule or hepatic hi-
lum if present. This method takes advantage of the fact
that the degree of Sirius red staining measured by the
degree of saturation of the red hue (0.1 to  0.04 of the
hue–saturation–intensity color model) correlates well
with chemically determined collagen content and mor-
phometrically determined estimates of the area of hepatic
fibrosis. This approach relies on the analysis of identical
brightfield images and images obtained with polarizing
filters to subtract background mathematically at each
pixel without interactive thresholding. The collagen con-
tent per unit area of the specimen is expressed in arbitrary
units calculated as the sum of the pixel-wise collagen mea-
surements divided by the number of summed pixels, cor-
rected for the section thickness as measured by a confocal
laser scanning microscope (Zeiss LSM 310) and multi-
plied by 5 (a constant) to yield a range of values very
similar to those obtained by methods that measure the
fractional area of fibrous tissue. The surface area of each
specimen was computed as the number of pixels multi-
plied by the pixel size (8.2  106 mm2). Because the
method uses the degree of saturation of color to estimate
collagen content, a pixel that is darker red (i.e., more
saturated), has greater weight than one that is paler red,
and although the values obtained do not have a physical
dimension, the relative amount of collagen can be com-
pared between specimens and used as a continuous func-
tion in statistical analyses. All collagen in the specimen is
measured by this method, including the small amount
normally present in portal tracts and central veins; there-
fore, biopsy specimens with relatively little abnormal fi-
brous tissue are not readily distinguished by this method.
Similarly, because only collagen is measured, expansion of
portal tracts by inflammation but not fibrosis does not
affect the result. Reproducibility, assessed by 10 collagen
measurements on the same slide, yielded a coefficient of
variation of 7.1% for biopsy specimens with high collagen
content (0.1 U) and 12.1% for those with low collagen
content (0.05 U).
Selection of Biopsy Specimens for Morphometric
Analysis. This dataset was limited to 535 HALT-C Trial
patients with at least two adequate liver specimens suit-
able for computerized morphometry. Fragmented speci-
mens (19% overall, 23% of baseline biopsies) were
excluded because of inherent inaccuracy, and biopsy spec-
imens with 10 mm2 of tissue were excluded to reduce
sampling variability. One hundred ninety-nine patients
met the criteria for all three biopsy specimens; another
135 patients had adequate specimens at baseline and bi-
opsy 2; an additional 136 patients had adequate speci-
mens for biopsy 2 and biopsy 3 but not at baseline; and an
additional 65 had adequate specimens for morphometry
at baseline and biopsy 3 but not in biopsy 2. Overall 1,269
specimens from 535 of the 1,050 randomized patients
were used in the analyses of morphometric data. These
included 1,267 needle biopsies and tissue from two ex-
planted livers. The 1,267 needle biopsies had a mean 
standard deviation length of 2.0  0.7 cm (median 1.9
cm) and a mean  standard deviation area of 17.5  5.8
mm2. There were 324 (31%) that were less than 15 mm
long. The sections from the two explant livers had 89 and
251 mm2 of tissue.
Statistical Analysis. To evaluate the change in mor-
phometric collagen over time, we used repeated-measures
analysis of variance assuming an autoregressive covariance
structure. Time (baseline, biopsy 2, biopsy 3), random-
ization stratum (lead-in nonresponders, breakthrough/re-
lapse patients, express patients) and the development of a
clinical outcome (yes/no) were included as fixed effects.
Correlation was measured by way of Spearman rank cor-
relation. Mann-Whitney and Kruskal-Wallis tests were
used for assessing differences in patient characteristics be-
tween groups. Contingency tables were analyzed with the
chi-square test. P values were two-sided. All analyses were
performed with SAS version 9.1 (SAS Institute, Inc.,
Cary, NC) or Instat version 3.06 (Graphpad Software,
San Diego, CA).
Results
Patient Population. The baseline characteristics of
the 535 patients whose biopsy specimens were used for
morphometric analysis were similar to those of the entire
randomized cohort of the HALT-C Trial (Table 1). The
mean age was 50, the majority were male (72%), and 95%
were infected with HCV genotype 1. Baseline liver biopsy
revealed cirrhosis in 182 (34%) of the 535 morphometry
patients compared with 41% in the overall HALT-C
Trial cohort, reflecting the fact that cirrhotic patients were
more likely to have fragmented or small biopsies.
Among the 535 patients in whom morphometric anal-
yses were performed, 346 (65%) were randomized at the
end of the lead-in phase, 78 (15%) were breakthrough/
relapse patients, and 111 (21%) were express patients. A
noteworthy difference among these three randomization
strata was in the interval between the baseline biopsy and
biopsy 2 (Table 2). The majority of the lead-in nonre-
sponder subgroup had the baseline liver biopsy shortly
before the start of the lead-in phase, with a median of 6.3
months (range 5.2-17.5 months) between biopsy and ran-
domization. Most of the breakthrough/relapse patients
were also biopsied just before entering the lead-in phase,
but nearly all had finished 48 weeks of combination ther-
apy and 24 weeks of follow-up before being randomized;
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therefore, the median time between baseline biopsy and
entry into the randomized phase was 18.1 months (range
0.8-25.9 months). Finally, most of the express patients
had baseline biopsies after they had failed peginterferon-
ribavirin therapy, with a median of 1.5 months (range
0.3-19.1 months) from biopsy to randomization. For all
patients, biopsy 2 was scheduled to be at 18 months after
entering the randomized phase; therefore, for the lead-in
nonresponder patients, biopsy 2 was a median of 25
months from baseline, whereas for breakthrough/relapse
patients and for express patients, biopsy 2 was obtained a
median of 37 months and 21 months after baseline, re-
spectively. Biopsy 3, on the other hand, was obtained at a
median of 24 months following biopsy 2 for all patients.
Changes in Fibrosis Stage. All liver specimens from
the 535 morphometry patients were scored for Ishak fi-
brosis stage by the pathology committee in blinded review
sessions. Three patients had no biopsy 2, and two were
missing biopsy 3, but all others had fibrosis stages assigned
at each of the three time points. Overall, between baseline
and biopsy 2, 30% of patients had an improvement (i.e.,
decrease) of 1 or more stages in Ishak fibrosis score, 43%
remained the same, and 27% worsened, with an increase
in stage (Table 3). Between biopsy 2 and biopsy 3, 26%
improved, 41% remained the same, and 33% worsened.
From baseline to biopsy 3, 32% improved, 34% remained
the same, and 34% had worsening of Ishak fibrosis score.
No significant differences emerged between patients as-
signed to the long-term peginterferon treatment arm and
those assigned to the untreated control arm, but there
were differences among the three randomization strata.
The distribution of fibrosis scores at the three time points
for each stratum and for the entire cohort is shown in Fig.
2. For the entire cohort, the number of patients with stage
3 fibrosis decreased, and the number with stages 2 and 1
increased, but the total proportion of patients with rela-
Table 1. Characteristics of Patients with Two Consecutive
Unfragmented Liver Biopsies Analyzed for Morphometry


















Mean  SD 30  5 30  5
Range 18–56 18–58
Diabetes 24% 24%
Genotype 1 95% 94%
Log10 HCV RNA (mean) 6.5  0.5 6.4  0.5
Randomization stratum





Long-term peginterferon 49% 49%
Baseline liver biopsy n  399 n  1,050
Fragmented 0 24%
Length (mean  SD) 21  7 mm 18  9 mm
Area (mean  SD) 18  6 mm2 14  8 mm2
Inflammation score (Ishak)
Mean 7.74  1.91 7.54  2.06
Range 3-12 1–12
Fibrosis score (Ishak)
Stage 2 11% 7%
Stage 3 39% 34%
Stage 4 17% 18%
Stage 5 21% 22%
Stage 6 13% 19%
Steatosis (5% of tissue) 39% 42%







Baseline to randomization, months 6.3 (5.2–17.5) 18.1 (0.8–25.9) 1.5 (0.3–19.1)
Baseline to biopsy 2, months 25.3 (22.6–40.5) 36.8 (19.7–48.9) 21.4 (14.2–40.5)
Biopsy 2 to biopsy 3, months 24.2 (15.7–37.9) 23.7 (13.1–32.3) 23.9 (14.0–29.6)
Values are expressed as the median (range).
Table 3. Changes in Ishak Fibrosis Scores During the HALT-
C Trial for the 535 Patients Used in Morphometric Analyses
n Improved Same Worsened
Baseline to biopsy 2 532 30% 43% 27%
IFN-treated 261 31% 40% 29%
Control 271 30% 44% 26%
Month 24 to biopsy 3 531 26% 41% 33%
IFN-treated 261 28% 40% 32%
Control 270 24% 42% 34%
Baseline to biopsy 3 533 32% 34% 34%
IFN-treated 262 33% 34% 33%
Control 271 31% 34% 35%
Three patients were missing biopsy 2 and two were missing biopsy 3. A score
was considered improved if it decreased by one or more stages and worsened if
it increased by one or more stages.
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tively mild fibrosis (stages 1-3) remained constant (47%-
49%), whereas patients with stage 6 (established cirrhosis)
increased from 14% at baseline to 20% in biopsy 2 to
26% in biopsy 3, with a corresponding decrease in stages
4 and 5 at each time point. Closer inspection of the three
randomization strata revealed an increasing proportion of
low scores (stages 1-3) as well as stage 6 and a decreasing
proportion of stages 4 and 5 in the breakthrough/relapse
group, suggesting that some patients may have benefitted
from partial virologic suppression that was achieved in
this group. The lead-in nonresponders and express pa-
tients tended to have worsening fibrosis scores. Differ-
ences between breakthrough/relapse patients and the
other two strata were significant at biopsy 2 (P  0.01)
and biopsy 3 (P  0.0004).
Morphometry. Morphometric determination of col-
lagen content was limited to the 1,269 unfragmented bi-
opsies with at least 10 mm2 of tissue, including 399
baseline, 470 biopsy 2, and 400 biopsy 3 specimens.
Overall, a similar relationship and significant correlation
occurred (Spearman r  0.57) between fibrosis stage and
collagen content as reported in other studies (6,7); how-
ever, considerable overlap was observed in the amount of
collagen at the various stages (Fig. 3), indicating that,
while correlated, morphometry, which quantifies the
amount of fibrous tissue, and Ishak fibrosis score, which
relies primarily on location of fibrosis and architectural
distortion, measure different things.
Using repeated measures analysis of variance, we found
no differences in mean morphometrically determined col-
lagen content over time between the peginterferon-
treated patients and the untreated controls (Fig. 4).
Surprisingly, however, the mean collagen content in-
creased by 49% between baseline and biopsy 2 (95% con-
fidence interval [CI] 35%-63%) but then further
increased only slightly to 54% above baseline at biopsy 3
(95% CI 41%-68%). Because we had anticipated that
fibrosis progression would be more linear over time, we
undertook additional analyses.
A potential explanation for the unexpected results in
overall collagen change with time was found in the strik-
ing differences among the three randomization strata
(Fig. 5). Patients randomized at the end of the lead-in
phase behaved closest to expectation, with an increase in
mean collagen by 61% over baseline (95% CI 47%-76%)
in biopsy 2 (median 25.3 months after baseline) and 80%
in biopsy 3 (95% CI 61%-99%; median 49.5 months
after baseline), although the difference between biopsy 2
and biopsy 3 was not statistically significant. In contrast,
the breakthrough/relapse patients had slightly less mean
collagen at baseline, with an increase of 48% in biopsy 2
(95% CI 8%-89%; median 36.8 months after baseline),
Fig. 2. Distribution of Ishak fibrosis stages at each biopsy among 535 patients used for morphometric analyses, showing an increasing proportion
of patients with stage 6 cirrhosis (P  0.0001). Panels show the three randomization strata with lead-in nonresponders (upper left [n  346]),
breakthrough/relapse (upper right [n  78]), express (lower left [n  111]), and the total cohort (lower right [n  535]). There were no significant
differences among the three strata at baseline. All three strata showed a significant increase in cirrhosis, but there were significantly fewer
breakthrough/relapse patients with advanced stages at biopsy 2 (P  0.01) and biopsy 3 (P  0.004) than in the other two strata.
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but no further increase in biopsy 3 (median 60.5 months
after baseline). The express patients were quite different;
their baseline biopsies followed an unsuccessful course of
peginterferon/ribavirin, rather than preceding the lead-in
course of therapy that the other two groups received.
Compared with the lead-in nonresponder patients, ex-
press patients had a mean of 47% more collagen at base-
line (P  0.0001). Collagen in biopsies 2 and 3 were not
significantly different from baseline levels, with an in-
crease of only 21% in biopsy 2 (95% CI 1%-40%; me-
dian 21.4 months after baseline) and then a shift back to
the baseline value in biopsy 3 (median 45.3 months after
baseline). The greater mean collagen content at baseline
in the express patients was not explained by differences
from the other groups in age, serum alanine aminotrans-
ferase, level of HCV RNA, alcohol history12 or by inflam-
mation or fat in the biopsy (Table 4). Within each of the
three randomization strata, no significant differences oc-
curred in mean collagen content at the various time points
between those randomized to long-term peginterferon
and the untreated controls (data not shown). The lead-in
nonresponder patients had an increase in mean collagen
Fig. 3. Distribution of measure-
ments of collagen content at each
Ishak fibrosis stage for the 1,269
liver biopsies in the study. The boxes
represent the median, 25th, and 75th
percentiles; the lines represent the
2.5 and 97.5 percentiles (outliers
not shown). Spearman correlation
coefficient  0.57 (P  0.0001).
Fig. 4. Mean collagen content
( standard error of the mean) for
the 535 patients in the study by
treatment group, showing no differ-
ence between long-term IFN and un-
treated controls at any of the three
time points.
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of 20% to 30% per year, the breakthrough/relapse pa-
tients had an increase of 10% to 16% per year, and the
express patients had an increase of 0% to 13% per year.
We also examined the possibility that patients with the
most substantial fibrosis progression may have suffered clin-
ical outcomes (death, ascites, variceal hemorrhage, spontane-
ous bacterial peritonitis, Child-Turcotte-Pugh score 7,
eligibility for liver transplantation, or hepatocellular carcino-
ma)11 and failed to have biopsy 3, resulting in a selection bias
that could account for the apparent lack of progression be-
tween biopsy 2 and biopsy 3. In fact, however, all but one of
the 535 patients in this analysis had a biopsy 3, even though
only 400 were unfragmented with at least 10 mm2 of tissue,
a requirement for inclusion in this analysis. Next, we asked
whether fragmented, small biopsies, which were excluded in
this analysis, were more likely to occur in biopsy 3, another
potential source of selection bias. Patients who suffered out-
comes had a 119% increase in mean collagen between base-
line and biopsy 3 (95% CI 79%-159%) and significantly
more mean collagen at each of the three time points (P 
0.0137 at baseline; P  0.0030 for biopsy 2; P  0.0031 for
biopsy 3) (Fig. 6) than patients without outcomes, even
though only 19 patients with outcomes had biopsy 3 speci-
mens adequate for morphometric analysis. Thus, patients
with clinical outcomes had both the most fibrosis at baseline
and the largest increase in fibrosis progression over time;
however, because patients with outcomes had such elevated
levels of fibrosis, they were less likely to have a biopsy suitable
for morphometric analysis. Although the number of patients
with clinical outcomes and fragmented/small biopsies is
small, exclusion of their biopsy 3 specimens from morpho-
metric analysis could have been partly responsible for the
apparent deceleration in fibrosis between biopsy 2 and bi-
opsy 3.
Finally, we examined the effect of baseline collagen on
changes in morphometric fibrosis determinations (Fig. 7).
Fig. 5. Mean collagen content
( standard error of the mean) at
different time points for the 535 pa-
tients in the study by randomization
strata. The median interval between
baseline biopsy and biopsy 2 was
36.8 months for the breakthrough/
relapse patients, 25.3 months for
the end of lead-in patients, and
21.4 months for the express pa-
tients. Mean collagen in biopsy 2
was significantly greater than in the
baseline biopsy for lead-in nonre-
sponders (P  0.0001) and break-
through/relapse patients (P 
0.0029), but biopsy 3 was not sta-
tistically significantly greater than bi-
opsy 2 for either group. Express
patients had significantly more col-
lagen in the baseline biopsy than
lead-in and breakthrough/relapse
patients (P  0.0001), but the dif-
ferences between baseline biopsy,
biopsy 2, and biopsy 3 for express
patients were not statistically
significant.






(n  111) P Value
Age* 50.3  7.6 48.7  4.9 50.2  6.4 0.21
Alanine aminotransferase* 110  71 113  94 101 74 0.51
Log HCV RNA* 6.46  0.47 6.58  0.44 6.38  0.59 0.02
Total lifetime alcoholic drinks (thousands)*12 15.5  23.3 22.9  43.0 17.7  24.7 0.09
Histology at baseline
Inflammation score5 7.6  1.9 7.3  2.0 7.6  2.0 0.40
Steatosis (5% of tissue) n  145 (42%) n  22 (28%) n  43 (57%) 0.08
Values are expressed as the mean  standard deviation.
*At randomization.
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We chose ranges to approximate the highest (0.055 units,
n  181), middle (0.024-0.055 units, n  158), and lowest
(0.024 units, n  185) third of baseline values. The mean
collagen of the cohort with medium baseline collagen be-
haved closest to expected, increasing by 110% above baseline
at biopsy 2 and 158% at biopsy 3. For those with low base-
line collagen, the mean increased by approximately the same
absolute value, but because the initial mean value was very
low, the percentage increase was high (307%), but there was no
further increase atbiopsy3.Finally, themeanof the cohortwith
high collagen actually fell by 10% at biopsy 2, but remained the
same at biopsy 3. This may be explained in part by loss of pa-
tients with the most collagen to clinical outcomes (Fig. 6), al-
though a complete explanation remains elusive.
Discussion
In this study, we found that with morphometric image
analysis, the most sensitive histologic method for measuring
fibrosis, long-term low-dose maintenance peginterferon
Fig. 6. Mean collagen content
( standard error of the mean) at
different time points showing signif-
icantly more fibrosis at each time
(baseline, P  0.0137; biopsy 2,
P  0.0030; biopsy 3, P 
0.0031) in the 42 patients who had
clinical outcomes than in the 493
patients who did not have an
outcome.
Fig. 7. Mean collagen content
( standard error of the mean) for
the 535 patients in the study by
baseline collagen levels (approxi-
mately one-third of patients in each
group). The group with high (.055
units) baseline collagen tended to
have less in subsequent biopsies,
whereas those with medium or low
collagen increased.
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therapy had no effect on fibrosis progression in this group of
patients with chronic hepatitis C. Our data, however, did
suggest that partial virologic suppression by full-dose pegin-
terferon/ribavirin during the lead-in phase may retard fibro-
sis progression. Moreover, our observations raise the
possibility that when full-dose peginterferon/ribavirin ther-
apy is ineffective in producing virologic suppression, fibrosis
progression may actually be accelerated.
In two previously completed short-term clinical trials
in patients with chronic hepatitis C, collagen was found to
increase at a relatively rapid rate that could be detected
and quantified by morphometry in large cohorts. In nei-
ther of these trials did the study drug have any effect on
changes in fibrosis; therefore, data from placebo-treated
controls and patients receiving study drugs were com-
bined for analyses of fibrosis progression. In one study,
245 patients with advanced fibrosis (Ishak stage 4-6) had
a 58% increase in mean collagen in 1 year.7 In another,
209 patients with moderate (stage 2-4) fibrosis had a 30%
increase in mean collagen of 30% in 1 year.9
The HALT-C Trial provided the opportunity to study
longer-term changes in fibrosis; however, because all pa-
tients received at least 6 months of ribavirin with full-dose
peginterferon, the trial did not include a true placebo-
treated control cohort. Nevertheless, this study was antic-
ipated to provide information about the long-term
progression of fibrosis, but the overall results (Fig. 4) were
surprising. The mean fibrosis of the cohort increased by
nearly 50% between baseline and biopsy 2, similar to
results reported in previous studies; thereafter, almost no
change occurred over the next 2 years of the study. To
some extent, we could explain these observations by in-
voking the differences in hepatic collagen results among
the three randomization strata (lead-in nonresponder,
breakthrough/relapse, and “express) (Fig. 5), and the in-
clusion of fewer biopsy 3 specimens resulting from the
loss of patients with the most fibrosis to clinical outcomes
(Fig. 6).
The three randomization strata differed from one an-
other in three important ways. First, a considerable dif-
ference existed in the time interval between the baseline
biopsy and biopsy 2, which averaged 25.3 months for the
lead-in nonresponder group, 36.8 months for the break-
through/relapse group, and 21.4 months for the express
group. Second, the breakthrough/relapse patients
achieved complete virologic suppression for several
months, which did not occur in the other two groups.
Third, the express patients underwent their biopsies after
6 months of full-dose peginterferon/ribavirin, whereas
the other patients underwent baseline biopsies before re-
ceiving therapy.
The cohort of patients randomized at the end of
lead-in therapy had fibrosis progression closest to that
reported previously, with an increase of 80% in hepatic
fibrosis over 4 years. Although this approximately 20%
per year is less than the 30% to 58% per year observed in
other studies, the current study is the first to include long-
term follow-up biopsies. The fibrosis progression we ob-
served in this group was not linear, however; the increase
was greater during the first 2 years than during the second
2 years. This observation may have resulted in part from
the loss of patients who had outcomes (Fig. 6). The break-
through/relapse patients had documented virologic sup-
pression for at least part of their treatment courses, which
may have contributed to the accumulation of consider-
ably less fibrosis, 50% over 5 years or 10% per year, and
relatively fewer patients with cirrhosis (Fig. 2). Within the
breakthrough/relapse cohort, however, no significant dif-
ference emerged between patients who received long-term
low-dose peginterferon and untreated controls; therefore,
the retardation they had in fibrosis progression appears to
have resulted from the initial viral suppression rather than
from maintenance therapy. Additionally, preliminary
analyses of clinical outcomes and histologic improvement
suggest that the impact of lead-in therapy was more sub-
stantial than the impact of maintenance therapy.13 Simi-
lar to the lead-in nonresponder cohort, the most
substantial increase in mean fibrosis for the breakthrough/
relapse group occurred between the baseline biopsy and
biopsy 2.
Fibrosis changes observed in the express patients are
not readily explained but accounted for much of the ap-
parent lack of fibrosis progression between biopsy 2 and
biopsy 3 in the entire cohort (Fig. 4). Even though express
subjects did not differ significantly in baseline Ishak fibro-
sis stages from that in the lead-in nonresponder stratum,
mean fibrosis as determined by morphometry was 47%
higher at baseline in the express group. Measured collagen
levels in the express group and the lead-in nonresponder
group were nearly the same in biopsy 2 but fell inexplica-
bly thereafter in the express group. What distinguished
the express group from the lead-in nonresponder group
was the fact that the express group had baseline biopsies
shortly (a median of 1.5 months) after failing to respond
to treatment with peginterferon/ribavirin. This observa-
tion raises the possibility that ineffective peginterferon
and ribavirin therapy might accelerate hepatic fibrosis
transiently and might also explain why the patients ran-
domized at the end of the lead-in phase (lead-in nonre-
sponders) had a greater increase in fibrosis during the first
2 years (during which they received ineffective full-dose
peginterferon and ribavirin therapy for the initial 6
months) than during the second 2-year interval. Cur-
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rently, however, a possible role of peginterferon and riba-
virin in promoting transient fibrosis progression remains
speculative.
A limitation of the current study is the fact that fewer
than half of the patients enrolled in the HALT-C Trial
had liver biopsies suitable for morphometric analysis, rais-
ing the possibility of selection bias. This observation dem-
onstrates the need for a standardized biopsy approach in
studying changes in hepatic fibrosis. Noninvasive tech-
niques may become available in the future but will need to
be validated against the natural history of the disease and
to be correlated with liver biopsy. If biopsies are to be used
as a study endpoint or as a standard for validation of
noninvasive markers, then the techniques and require-
ments for adequacy of biopsy specimens need to be stan-
dardized. For studies of fibrosis, specimens obtained with
cutting biopsy needles are superior to those obtained with
suction needles14; in addition, larger-gauge needles (14-
to 16-gauge) and biopsies at least 2 cm long are most likely
to provide adequate specimens for assessing histology15 if
this is to be used as a clinical trial endpoint and to corre-
late with noninvasive markers. Biopsy sampling error will
always be present to some extent, so it must be empha-
sized that morphometry is not appropriate for evaluation
of changes in individual patients but should be reserved
for statistical analysis and comparison of changes in large
cohorts.
The availability of serial liver biopsy specimens during
the HALT-C Trial provided an opportunity, for the first
time, to analyze fibrosis progression by way of quantita-
tive image analysis over 3.5 to 5 years in a large number of
patients with advanced chronic hepatitis C. Our findings
show promise for this approach in future studies and clin-
ical trials, but at present the natural history of fibrosis
progression remains an area of great uncertainty. There-
fore, in the future, carefully designed prospective long-
term studies such as the HALT-C Trial will be needed to
define the true natural history of fibrosis in chronic hep-
atitis C.
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bor, MI (contract N01-DK-9-2323; grant M01RR-00042;
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(contract N01-DK-9-2322; grant M01RR-00065); T. Jake
Liang, David Kleiner, Yoon Park, Elenita Rivera, and Van-
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stitute of Diabetes and Digestive and Kidney Diseases,
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